List of Excipients in API enasidenib mesylate
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing enasidenib mesylate
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Celgene Corporation | IDHIFA | enasidenib mesylate | 59572-705 | CELLULOSE, MICROCRYSTALLINE | 2034-09-16 |
| Celgene Corporation | IDHIFA | enasidenib mesylate | 59572-705 | FERRIC OXIDE YELLOW | 2034-09-16 |
| Celgene Corporation | IDHIFA | enasidenib mesylate | 59572-705 | HYDROXYPROPYL CELLULOSE | 2034-09-16 |
| Celgene Corporation | IDHIFA | enasidenib mesylate | 59572-705 | HYPROMELLOSE ACETATE SUCCINATE 06081224 | 2034-09-16 |
| Celgene Corporation | IDHIFA | enasidenib mesylate | 59572-705 | MAGNESIUM STEARATE | 2034-09-16 |
| Celgene Corporation | IDHIFA | enasidenib mesylate | 59572-705 | POLYETHYLENE GLYCOL | 2034-09-16 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for enasidenib mesylate
Excipient focus: CELLULOSE, MICROCRYSTALLINE
enasidenib mesylate drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
enasidenib mesylate drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
enasidenib mesylate drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE ACETATE SUCCINATE 06081224
enasidenib mesylate drug variants containing HYPROMELLOSE ACETATE SUCCINATE 06081224
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing HYPROMELLOSE ACETATE SUCCINATE 06081224
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
enasidenib mesylate drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
enasidenib mesylate drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
enasidenib mesylate drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
enasidenib mesylate drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
enasidenib mesylate drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
enasidenib mesylate drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
enasidenib mesylate drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
enasidenib mesylate drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Celgene Corporation | enasidenib mesylate | 59572-705 |
| >Company | >Ingredient | >NDC |
enasidenib mesylate drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
